Evidence map›Paper›PMID 25758612›Full record

ArticleScientific reports2015

Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.

Andrea Weiss, Débora Bonvin, Robert H Berndsen, Edoardo Scherrer, Tse J Wong, Paul J Dyson, Arjan W Griffioen, Patrycja Nowak-Sliwinska

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Dichloro Ru(II)-ACS pharmacology & translational science · 2023
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Andrea Weiss1] Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland [2] Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center Amsterdam, The Netherlands.
Débora BonvinInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Robert H Berndsen1] Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland [2] Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center Amsterdam, The Netherlands.
Edoardo ScherrerInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Tse J WongAngiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center Amsterdam, The Netherlands.
Paul J DysonInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Arjan W GriffioenAngiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center Amsterdam, The Netherlands.
Patrycja Nowak-Sliwinska1] Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland [2] Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center Amsterdam, The Netherlands.
École Polytechnique Fédérale de Lausanne · CHAmsterdam UMC Location VUmc · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor vasculature is known to be poorly organized leading to increased leakage of molecules to the extravascular space. This process can potentially increase interstitial fluid pressure impairing intra-tumoral blood flow and oxygen supply, and can affect drug uptake. Anti-angiogenic therapies are believed to reduce vascular permeability, potentially reducing interstitial fluid pressure and improving the extravasation of small molecule-based chemotherapeutics. Here we show that pretreatment of human ovarian carcinoma tumors with sub-optimal doses of the VEGFR targeting tyrosine kinase inhibitor axitinib, but not the EGFR targeting kinase inhibitor erlotinib, induces a transient period of increased tumor oxygenation. Doxorubicin administered within this window was found to enter the extravascular tumor space more rapidly compared to doxorubicin when applied alone or outside this time window. Treatment with the chemotherapeutics, doxorubicin and RAPTA-C, as well as applying photodynamic therapy during this period of elevated oxygenation led to enhanced tumor growth inhibition. Improvement of therapy was not observed when applied outside the window of increased oxygenation. Taken together, these findings further confirm the hypothesis of angiostasis-induced vascular normalization and also help to understand the interactions between anti-angiogenesis and other anti-cancer strategies.

Indexed as

Neovascularization, PathologicPhotochemotherapyAngiogenesis InhibitorsAnimalsAntineoplastic AgentsAxitinibCell Line, TumorChick EmbryoCombined Modality TherapyCymenesDisease Models, AnimalDoxorubicinDrug SynergismHumansImidazolesIndazolesAngiogenesis InhibitorsAntineoplastic AgentsAxitinibCymenesdichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II)DoxorubicinImidazolesIndazolesIndolesOrganometallic CompoundsProtein Kinase InhibitorsPyrrolesSunitinib

Identifiers

PMID25758612
PMCPMC4355632
OpenAlexW2055204590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.